Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. Show more
Location: One Broadway, Cambridge, MA, 02142, United States | Website: https://www.nuvalent.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
5.781B
52 Wk Range
$55.53 - $113.51
Previous Close
$80.50
Open
$80.62
Volume
299,198
Day Range
$79.53 - $81.00
Enterprise Value
4.406B
Cash
1.073B
Avg Qtr Burn
-50.95M
Insider Ownership
2.85%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Zidesamtinib (NVL-520) Details Non-small cell lung carcinoma, Cancer, Solid tumor/s | NDA Submission | |
NVL-655 Details Cancer, Non-small cell lung carcinoma | Phase 3 Initiation | |
Neladalkib (NVL-655) Details Solid tumor/s, Non-small cell lung carcinoma, Cancer | Phase 2 Data readout | |
NVL-330 Details HER2-expressing cancers, Cancer, Non-small cell lung carcinoma | Phase 1a Data readout |